A61K 47/6859
The tumour determinant being from liver or pancreas cancer cell
Official title: {the tumour determinant being from liver or pancreas cancer cell}
A61K47/6859 (The tumour determinant being from liver or pancreas cancer cell) appears on 202 US grants and 320 published applications in this corpus.
Search patents in A61K- Granted patents
- 202
- Published applications
- 320
- Assignees
- 123
- Inventors
- 547
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 2 |
| 2006 | 0 | 3 |
| 2007 | 0 | 2 |
| 2008 | 0 | 3 |
| 2009 | 2 | 7 |
| 2010 | 4 | 4 |
| 2011 | 4 | 12 |
| 2012 | 5 | 10 |
| 2013 | 10 | 16 |
| 2014 | 7 | 24 |
| 2015 | 25 | 25 |
| 2016 | 26 | 38 |
| 2017 | 16 | 25 |
| 2018 | 26 | 31 |
| 2019 | 8 | 22 |
| 2020 | 14 | 16 |
| 2021 | 20 | 19 |
| 2022 | 6 | 8 |
| 2023 | 8 | 9 |
| 2024 | 6 | 22 |
| 2025 | 6 | 13 |
| 2026 | 5 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Humanized anti-GPC-1 antibody2 Jun 2026US 12,643,955 B2Iwate Medical University
- Antibody-drug conjugate having acidic self-stabilization junction21 Apr 2026US 12,605,458 B2Systimmune, Inc.
- Protein-drug conjugates comprising camptothecin analogs and methods of use thereof21 Apr 2026US 12,605,459 B2Regeneron Pharmaceuticals, Inc.
- Method of conjugation of Cys-mAbs7 Apr 2026US 12,594,342 B2Amgen Inc.
- Therapeutic targeting of Cadherin 11 in cancer13 Jan 2026US 12,522,657 B2The Brigham and Women S Hospital, Inc.
- Humanized Anti-GPC-1 Antibody24 Sep 2026US 2026/0286004 A1Iwate Medical University
- Anti-gpc1 monoclonal antibody, therapeutic and diagnostic uses thereof4 Jun 2026US 2026/0152569 A1
- Combination of antibody-drug conjugate and tubulin inhibitor21 May 2026US 2026/0139074 A1Daiichi Sankyo Company, Limited
- Cd138/syndecan1 antibodies and methods of use thereof14 May 2026US 2026/0131036 A1
- Cdh17-binding antibodies and methods of use thereof30 Apr 2026US 2026/0115303 A1Antharis Therapeutics Inc.
Most cited
By later US patents
- Immunoconjugates with an intracellularly-cleavable linkage115US 7,999,083 B2Immunomedics, Inc. · 2011
- Camptothecin-binding moiety conjugates110US 7,591,994 B2Immunomedics, Inc. · 2009
- Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer87US 9,233,125 B2University of Maryland, Baltimore · 2016
- Immunoconjugates with an intracellularly-cleavable linkage85US 8,080,250 B1Immunomedics, Inc. · 2011
- Camptothecin-binding moiety conjugates76US 8,268,317 B2Immunomedics, Inc. · 2012